Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

39
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
39

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Curricular Content Reduction on Student-Reported Mental and Physical Health.

American journal of pharmaceutical education·2025
Same author

Knowledge of Kratom among Alabama Pharmacists.

Pharmacy (Basel, Switzerland)·2024
Same author

Effect of Interprofessional Clinical Debates on Attitudes of Interprofessional Teams.

PRiMER (Leawood, Kan.)·2021
Same author

EZ-Root-VIS: A Software Pipeline for the Rapid Analysis and Visual Reconstruction of Root System Architecture.

Plant physiology·2018
Same author

Overview of venous thromboembolism.

The American journal of managed care·2018
Same author

Implementation and Assessment of an Ambulatory Prescribing Guidance Tool to Improve Patient Safety in the Geriatric Population.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2017

Related Experiment Video

Updated: May 1, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Acquired Thrombophilia.

Emily M Armstrong1, Jessica M Bellone2, Lori B Hornsby3

  • 1Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, AL, USA Department of Internal Medicine, University of South Alabama, Mobile, AL, USA ekm0010@auburn.edu.

Journal of Pharmacy Practice
|April 19, 2014
PubMed
Summary
This summary is machine-generated.

Acquired thrombophilia, including Antiphospholipid Syndrome (APS) and Human Immunodeficiency Virus (HIV), increases venous thromboembolism (VTE) risk. Thrombophilia status generally doesn't change acute VTE treatment, except for APS.

Keywords:
acquired thrombophiliaantiphospholipid antibodieshuman immunodeficiency virusmalignancyoral contraceptivesthrombophilia

More Related Videos

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174

Related Experiment Videos

Last Updated: May 1, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174

Area of Science:

  • Hematology
  • Internal Medicine
  • Vascular Medicine

Background:

  • Acquired thrombophilia elevates venous thromboembolism (VTE) risk.
  • Antiphospholipid syndrome (APS) and Human Immunodeficiency Virus (HIV) are key acquired thrombophilias.
  • VTE risk factors in HIV patients include disease, host, and treatment elements.

Purpose of the Study:

  • To review acquired thrombophilia and its association with VTE.
  • To identify risk factors for VTE in specific populations.
  • To discuss implications for VTE treatment.

Main Methods:

  • Literature review of acquired thrombophilia and VTE.
  • Analysis of risk factors in HIV, malignancy, and oral contraceptive users.
  • Examination of treatment modifications based on thrombophilia status.

Main Results:

  • APS and HIV are significant acquired thrombophilias.
  • Malignancy and combined oral contraceptives (COCs) increase VTE risk.
  • High-risk COCs involve high-dose estrogen and specific progestins.

Conclusions:

  • Thrombophilia significantly impacts VTE risk across various conditions.
  • Except for APS, thrombophilia status does not alter acute VTE treatment in nonpregnant individuals.
  • Understanding these risk factors is crucial for VTE prevention and management.